AbbVie (ABBV) Q3 FY2026 earnings: revenue $17.4 billion, up 10.3% on the year

AbbVie Inc. (ABBV) announced its results for Q3 FY2026, the quarter ended 30 September 2026, on 30 October 2026. Revenue was $17.4 billion, up 10.3% on the same quarter a year earlier. Net income was $4.2 billion, up 2167.7% on the year, and diluted earnings per share $2.37. The figures are from the company's earnings press release; the 10-Q with the full statements is not filed yet, and this page fills in when it is.

Revenue$17.4 billionup 10.3%

Net income$4.2 billionup 2167.7%

Diluted EPS$2.37$0.10 a year earlier

QuarterQ3 FY2026ended 30 September 2026

What management said

Guidance figures: 2 raised.

Revenue grew about ten percent: Net revenues rose 10.3 percent on a reported basis and 10.5 percent on an operational basis, to $17.404 billion.
Diluted EPS higher on both bases: GAAP diluted EPS was $2.37 against $0.10 a year earlier. Adjusted diluted EPS was $3.82 against $1.86.
Immunology revenue rose 16 percent: Immunology net revenues were $9.165 billion, up 16.3 percent on a reported basis and 16.6 percent on an operational basis.

Read the earnings call summary

The quarter, against the one before and a year earlier

Line	Q3 FY2026	Q2 FY2026	Q3 FY2025	Change on the year
Revenue	17,404	16,990	15,776	+10.3%
Net income	4,218	3,613	186	+2167.7%
Diluted EPS	$2.37	$2.03	$0.10	+2270.0%

$ million except per share.

Q3 FY2026 is from the company's press release of 30 October 2026; the other columns are from its 10-Q and 10-K filings. A release figure is shown when the release's own figure for an earlier quarter matches the filed one, so the line and its units are read right.

Quarterly results, the last 20 quarters filed

	Q3 FY2021 †	Q4 FY2021	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026
Revenue	14,342	14,886	13,538	14,583	14,812	15,121	12,225	13,865	13,927	14,301	12,310	14,462	14,460	15,102	13,343	15,423	15,776	16,618	15,002	16,990
Cost of revenue	4,390	4,320	4,052	4,170	5,022	4,170	3,986	4,240	6,485	5,704	4,094	4,202	4,212	4,396	4,002	4,346	5,304	4,552	4,218	4,291
Gross profit	9,952	10,566	9,486	10,413	9,790	10,951	8,239	9,625	7,442	8,597	8,216	10,260	10,248	10,706	9,341	11,077	10,472	12,066	10,784	12,699
Gross margin	69%	71%	70%	71%	66%	72%	67%	69%	53%	60%	67%	71%	71%	71%	70%	72%	66%	73%	72%	75%
R&D	1,661	1,827	1,497	1,609	1,614	1,790	2,292	1,733	1,723	1,927	1,939	1,948	2,130	6,774	2,067	2,131	2,319	2,579	2,472	2,344
SG&A	3,083	3,260	3,127	5,412	3,304	3,417	3,039	3,268	3,372	3,193	3,315	3,377	4,205	3,855	3,293	3,253	3,569	3,895	3,578	3,632
Operating income	4,306	5,074	4,717	3,295	4,603	5,502	2,768	4,513	2,281	3,195	2,798	3,998	3,831	-1,490	3,733	4,894	1,904	4,544	3,990	6,432
Operating margin	30%	34%	35%	23%	31%	36%	23%	33%	16%	22%	23%	28%	26%	-10%	28%	32%	12%	27%	27%	38%
Interest expense	596	580	548	556	560	566	553	552	555	564	660	726	720	702	700	740	739	714	717	746
Pre-tax income	3,688	4,271	4,929	1,183	4,400	2,965	475	2,610	1,953	1,212	1,755	2,146	2,084	-2,269	1,661	1,554	714	2,668	1,039	4,278
Tax rate	14%	5%	9%	22%	10%	17%	49%	22%	9%	32%	22%	36%	25%	n/a	22%	39%	74%	32%	33%	15%
Net income	3,179	4,044	4,490	924	3,949	2,473	239	2,024	1,778	822	1,369	1,370	1,561	-22.0	1,286	938	186	1,816	695	3,613
Net margin	22%	27%	33%	6%	27%	16%	2%	15%	13%	6%	11%	9%	11%	-0%	10%	6%	1%	11%	5%	21%
Diluted EPS	$1.78	$2.26	$2.51	$0.51	$2.21	$1.38	$0.13	$1.14	$1.00	$0.46	$0.77	$0.77	$0.88	-$0.02	$0.72	$0.52	$0.10	$1.02	$0.39	$2.03
Operating cash flow	7,935	5,075	4,908	5,005	7,602	7,428	4,193	6,319	7,574	4,753	4,040	2,271	5,447	7,048	1,635	5,153	7,024	5,218	3,829	3,436
Capital expenditure	217	187	162	143	177	213	175	178	219	205	193	241	249	291	235	269	381	329	265	322
Free cash flow	7,718	4,888	4,746	4,862	7,425	7,215	4,018	6,141	7,355	4,548	3,847	2,030	5,198	6,757	1,400	4,884	6,643	4,889	3,564	3,114
Buybacks	6.0	131	1,470	9.0	4.0	4.0	1,955	10.0	4.0	3.0	1,324	9.0	17.0	358	961	12.0	4.0	3.0	1,489	9.0
Dividends paid	2,315	2,314	2,526	2,507	2,504	2,506	2,661	2,625	2,627	2,626	2,772	2,750	2,751	2,752	2,925	2,910	2,911	2,911	3,086	3,070
Shares outstanding	1,768m	1,769m	1,767m	1,768m	1,768m	1,769m	1,764m	1,765m	1,766m	1,766m	1,766m	1,766m	1,767m	1,765m	1,766m	1,767m	1,767m	1,768m	1,767m	1,767m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Earnings press release for the quarter ended 30 September 2026, filed with the SEC on 30 October 2026 with a Form 8-K: the release.